English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Blood cultures (BC) are ~50% sensitive for diagnosing IC. T2Candida (T2) detects five leading Candida spp. directly in blood and was ≥90%/90% sensitive/specific (S/Sp) for candidemia in clinical trials. Optimal use of T2 in clinical practice is unclear. We targeted T2 to specific ICU patients at-risk for IC, and implemented AF management algorithms developed with ICU teams. Methods A DS team ordered concurrent T2 and BC, and used results to guide AF in patients fulfilling pre-specified criteria for septic shock (medical ICU (MICU)), sepsis after abdominal surgery (trauma ICU), or sepsis with mechanical circulatory support (cardiothoracic ICU). We focused on groups with anticipated pre-test IC probabilities of ~3–15%. Proven IC was defined if BC+ and possible IC if BC- but a compatible clinical picture was observed. Results Seven percent (6/88) of BC in ICU patients with sepsis were Candida +. T2 and BC results are shown in the table. Using BC as gold standard, T2 S/Sp and PPV/NPV were 50%/87% and 33%/96%, respectively. Including possible IC, T2 S/Sp increased to 69%/96%, and 67% (4/6) of T2+/BC− results were likely true positive; two false-positive results were for C. parapsilosis. We focused on MICU outcomes initially since 75% (66/88) of tests were performed here. Empiric AFs were discontinued in 12 patients following a T2- result; AFs were avoided in all others. Median combined days of therapy (DOT)/month for caspofungin and fluconazole as empiric or definitive treatment prior to and after introducing DS were 26 (range: 10–53) and 15 (3–32), respectively (P = 0.0047). AF consumption was decreased 47% (figure). Conclusion Targeted DS using T2 in select ICU patients with sepsis significantly reduced AF usage. 14% of patients with sepsis were diagnosed with IC using either T2+ or BC+, compared with 7% with BC+ alone, as would be expected if BC S was 50%. T2 S and T2−/BC+ results were lower and higher, respectively, than previously reported, indicating that treatment decisions should be based on results of both tests. Most T2+/BC− results were ascribed to possible IC.Table. Rates of T2 and BC Positive Results and Corresponding Candida Species % (n) tests Candida spp. T2+ 10% (9) 5 CP, 4 CA/CT BC+ 7% (6) 5 CA, 1 CP T2+/BC+ 3% (3) 2 CA, 1 CP T2+/BC- 7% (6) 2 CA/CT, 4 CP T2-/BC+ 3% (3) 3 CA T2-/BC- 86% (76) Disclosures M. H. Nguyen, Merck: Grant Investigator, Research grant. Astellas: Grant Investigator, Research grant.

open forum infectious diseases

2033. Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A Successful Pilot Study of Diagnostic Stewardship (DS) Directed Toward Specific Intensive Care Unit (ICU) Patients At-Risk for Sepsis due to Invasive Candidiasis (IC)